Genomic score test may cut chemo use
2026-05-30
A lab report, not a drug, is now being cast as the most disruptive tool in breast cancer care. A new genomic scoring test, read from a small tumor sample, stratifies early-stage patients by recurrence risk and flags a large group whose tumors appear exquisitely hormone‑sensitive but poorly responsive to cytotoxic chemotherapy.
The striking claim is simple. Many can skip chemo. In a randomized trial, patients with low genomic scores who received endocrine therapy alone showed near-identical invasive disease‑free survival and overall survival compared with peers given combined chemotherapy plus hormone therapy, according to investigators. The assay integrates expression of multiple genes involved in cell proliferation and estrogen signaling, generating a numerical score that oncologists can plug into treatment algorithms alongside classic pathology, such as lymph‑node status and tumor grade.
Skeptics will argue that one test should not rewrite oncology. Yet health systems are already eyeing the cost calculus: shorter infusion chair queues, fewer cases of chemotherapy‑induced neutropenia, and less cardiotoxicity, traded against the price and accessibility of high‑complexity molecular diagnostics. For patients, the shift is even starker. Hair loss, nausea, and marrow suppression may, for many with low scores, give way to tablets that quietly modulate estrogen receptors and aromatase activity instead.
Loading...
